Page 174 - Read Online

Page 143 Hjalgrim et al. J Transl Genet Genom 2022;6:134-46 https://dx.doi.org/10.20517/jtgg.2021.46

DECLARATIONS
Authors’ contributions
Reviewed papers and authored the paper together: Hjalgrim H, Rostgaard K

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
Both authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2022.

REFERENCES
1. Ferlay J, Ervik M, Lam FM, et al. Global and Regional Estimates of the Incidence and Mortality for 38 Cancers: GLOBOCAN 2018.
Available from: https://gco.iarc.fr/today [Last accessed on 28 Jan 2022].
2. Hjalgrim H, Chang E, Glaser S. Hodgkin lymphoma. In: Thun MJ, Linet MS, Cerhan JR, Haiman CA, Schottenfeld D, editors. Cancer
epidemiology and prevention. New York: Oxford University Press; 2018. p. 745-66.
3. Shanbhag S, Ambinder RF. Hodgkin lymphoma: a review and update on recent progress. CA Cancer J Clin 2018;68:116-32. DOI
PubMed PMC
4. Biccler JL, Glimelius I, Eloranta S, et al. Relapse risk and loss of lifetime after modern combined modality treatment of young patients
with Hodgkin lymphoma: a Nordic lymphoma epidemiology group study. J Clin Oncol 2019;37:703-13. DOI PubMed
5. Caro J, Diefenbach C. New approaches to managing relapsed/refractory Hodgkin lymphoma: the role of checkpoint inhibitors and
beyond. Expert Rev Hematol 2021;14:741-50. DOI PubMed
6. Glimelius I, Diepstra A. Novel treatment concepts in Hodgkin lymphoma. J Intern Med 2017;281:247-60. DOI PubMed
7. Glimelius I, Ekberg S, Jerkeman M, et al. Long-term survival in young and middle-aged Hodgkin lymphoma patients in Sweden 1992-
2009-trends in cure proportions by clinical characteristics. Am J Hematol 2015;90:1128-34. DOI PubMed
8. Ng AK, van Leeuwen FE. Hodgkin lymphoma: late effects of treatment and guidelines for surveillance. Semin Hematol 2016;53:209-
15. DOI PubMed
9. Björkholm M, Weibull CE, Eloranta S, Smedby KE, Glimelius I, Dickman PW. Greater attention should be paid to developing
therapies for elderly patients with Hodgkin lymphoma-A population-based study from Sweden. Eur J Haematol 2018;101:106-14.
DOI PubMed
10. Glimelius I, Eloranta S, Ekberg S, Chang ET, Neovius M, Smedby KE. Increased healthcare use up to 10 years among relapse-free
Hodgkin lymphoma survivors in the era of intensified chemotherapy and limited radiotherapy. Am J Hematol 2017;92:251-8. DOI
PubMed
11. Glimelius I, Englund A, Rostgaard K, et al. Distribution of hospital care among pediatric and young adult Hodgkin lymphoma
survivors-A population-based cohort study from Sweden and Denmark. Cancer Med 2019;8:4918-27. DOI PubMed PMC
12. Carbone A, Gloghini A, Carlo-Stella C. Are EBV-related and EBV-unrelated Hodgkin lymphomas different with regard to
susceptibility to checkpoint blockade? Blood 2018;132:17-22. DOI PubMed
13. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms.
Blood 2016;127:2375-90. DOI PubMed PMC
14. Stein H, Delsol G, Pileri SA, Weiss LM, Poppema S, Jaffe ES. Classical Hodgkin lymphoma, introduction, In: Swerdlow SH, Campo
E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumours of haematopoietic and
lymphoid tissues. Lyon, France: International Agency for Research on Cancer; 2008. p. 326-9.
15. Correa P, O’Conor GT. Epidemiologic patterns of Hodgkin’s disease. Int J Cancer 1971;8:192-201. DOI PubMed
16. Cozen W, Kavianpour B, Mack TM. The epidemiology of Hodgkin lymphoma. In: Hudnall S, Küppers R, editors. Precision molecular
pathology of Hodgkin lymphoma. Springer International Publishing; 2017. p. 157-96. DOI